A Novel Gene Expression Signature-Based on B-Cell Proportion to Predict Prognosis of Patients with Lung Adenocarcinoma

Zhang Yi
  Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University

Yin Xuewen
  Cancer Institute of Jiangsu Province

Wang Qi
  The Affiliated Cancer Hospital of Nanjing Medical University

Song Xuming
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Xia Wenjie
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Mao Qixing
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Chen Bing
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Liang Yingkuan
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Zhang Te
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Xu Lin
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Jiang Feng (fengjiang_nj@njmu.edu.cn)
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Xu Xinyu
  Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University

Dong Gaochao
  Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University

Research Article

Keywords: B cells, lung adenocarcinoma, microenvironment, prognosis model, immunotherapy management
Abstract

Background: This study aimed to develop a reliable immune signature based on B-cell proportion to predict the prognosis and benefit of immunotherapy in LUAD.

Methods: The proportion of immune cells in the TCGA-LUAD dataset was estimated using MCP-counter. The Least Absolute Shrinkage and Selector Operation was used to identify a prognostic signature and validated in an independent cohort. We used quantitative reverse transcription-polymerase chain reaction (qRT-PCR) data and formalin-fixed paraffin-embedded (FFPE) specimens immunohistochemistry to illustrate the correlation between prognostic signature and leukocyte migration.

Results: We found that the relative abundance of B lineage positively correlated with overall survival. Then, we identified a 13-gene risk-score prognostic signature based on B lineage abundance in the testing cohort and validated it in a cohort from the GEO dataset. This model remained strongly predictive of prognoses across clinical subgroups. Further analysis revealed that patients with a low-risk score were characterized by B-cell activation and leukocyte migration, which was also confirmed in FFPE specimens by qRT-PCR and immunohistochemistry. Finally, this immune signature was an independent prognostic factor in the composite nomogram of clinical characteristics.

Conclusions: In conclusion, the 13-gene immune signature based on B-cell proportion may serve as a powerful prognostic tool in LUAD.

1. Introduction

Lung cancer is one of the malignant tumors with the highest morbidity and mortality worldwide; the overall 5-year survival rate is about 20% (1). Nonsmall cell lung cancers (NSCLCs) represent 85% of lung tumors. They encompass multiple cancer types, such as lung adenocarcinomas (LUADs), lung squamous cell carcinomas (LUSCs), and large-cell cancers. Among them, LUADs and LUSCs are the largest NSCLC subgroups (2). Therefore, effective treatments for LUAD have always been the focus of research. Over the past 10 years, the understanding of the immune system and its role in the development and progression of cancer has continued to deepen, leading to remarkable progress in the field of cancer immunotherapy (3). Immunotherapy has been widely used in the first-line and second-line treatments of NSCLC (4–6), which has inspired people's enthusiasm for elucidating the prognostic and pathophysiological effects of the tumor microenvironment (TME). The TME, including cancer-associated fibroblasts (7, 8), extracellular matrix (9), epithelial cells (10), myeloid cells (11), and tumor-infiltrating lymphocytes (12), affects the malignant progression and immune response of lung cancer. T cells and B cells are important components of tumor-infiltrating immune cells. The research on the functions and mechanisms of T cells is relatively comprehensive; however, the research on B cells is still insufficient.

Tumor-infiltrating B cells have emerged as key players in the TME. Chen and colleagues performed a single-cell RNA-seq analysis of cells isolated from patients with NSCLC and identified two major subtypes of B cells, namely the naïve-like and plasma-like B cells (13). They found that the naïve-like B cells
suppressed growth, while the plasma-like B cells promoted cell growth in the advanced stage of NSCLC, but inhibited cancer cell growth in the early stage of NSCLC. Wang and colleagues conducted a comprehensive genomic landscape of 149 NSCLC cases and revealed that highly clustered \textit{EGFR} mutations were associated with inflammatory tumor-infiltrating B lymphocytes, which was also confirmed in the TCGA dataset\cite{14}. Tumor-infiltrating B cells also served as local antigen-presenting cells by providing secondary stimulation to Immune infiltrating cells (TILs). Bruno and colleagues demonstrated that tumor-infiltrating B cells efficiently presented antigens to CD4$^+$ TILs and identified three CD4$^+$ TIL responses to tumor-infiltrating B cells, which were categorized as activated, antigen-associated, and nonresponsive\cite{15}. Hence, a new role was suggested for tumor-infiltrating B cells in their interplay with CD4$^+$ TIL in the TME. Whether tumor-infiltrating B cells have protumor or antitumor effect is still controversial.

Considering the important roles of B cells in the TME, which constitutes a potential novel therapeutic in NSCLC immunotherapy, a novel gene expression signature needed to be urgently developed based on B-cell proportion in patients with LUAD. Therefore, a prognosis signature based on B-cell proportion was established, which was a robust prognostic biomarker and predictive factor that could be used in the clinic.

2. Materials And Methods

2.1 RNA-sequencing data used to assess the abundance of immune-infiltrating cells

The gene expression data (workflow type: HTSeq-Counts) and the corresponding clinical information from the Cancer Genome Atlas (TCGA) website (https://gdc.cancer.gov/) were downloaded using the “TCGAbiolinks” R package (Version 2.14.1). Entrez IDs were converted into gene symbols using the Bioconductor package “org.Hs.eg.db” (Version 3.10.0). Genes with low expression were removed from the profile. The abundance of immune-infiltrating cells in each sample was assessed with the MCP-counter\cite{16}, which provided the abundance score for eight immune populations (T cells, CD8 $+$ T cells, cytotoxic lymphocytes, natural killer cells, B lineages, monocyctic lineage, myeloid dendritic cells, and neutrophils) and two stromal populations (endothelial cells and fibroblasts). The assessment of these cell subpopulations was based on the analysis of gene expression of cell markers. The MCP-counter signature composition of B lineages was as follows: \textit{BANK1}, \textit{CD19}, \textit{CD22}, \textit{CD79A}, \textit{CR2}, \textit{FCRL2}, \textit{IGKC}, \textit{MS4A1}, and \textit{PAX5}. The transcripts of other cell subpopulations were published by the algorithm’s author. All cell subpopulation abundances were normalized using the $Z$ score.

2.2 Differential expression analysis and construction of the B-lineage-associated risk signature

Differential expression analysis was performed using the “DESeq2” R package (Version 1.26.0) with the standard comparison mode between the two experimental conditions. LASSO algorithm, using the R
package “glmnet” (Version 3.0), was built to construct a B-lineage-associated risk signature. The “survival” R package (Version 3.5) was used to select the optimal cutoff value and plot Kaplan–Meier survival curves. The “timeROC” R package (Version 0.4) was used to conduct a time-dependent receiver operating characteristic (ROC) curve analysis.

2.3 Microarray data

The transcript expression matrixes from GSE31908, GSE29013, and GSE30219 based on the GPL570 platform, including 131 patients with LUAD, were downloaded from the Gene Expression Omnibus (GEO) database. In these matrixes, the gene expression data for three matrixes were subjected to log2 transformation. The scale method of the “limma” R package (Version 3.42.2) was used to normalize the data.

2.4 Patients with LUAD from Cancer Hospital Affiliated to Nanjing Medical University

A total of 12 patients who underwent surgery without neoadjuvant chemotherapy and were diagnosed with LUAD at Cancer Hospital Affiliated to Nanjing Medical University (Nanjing, China) were included. The Nanjing cohort consisted of formalin-fixed paraffin-embedded (FFPE) specimens collected from patients who underwent radical surgery between 2018 and 2020. Each patient underwent a standard radical surgical procedure, and all specimens were evaluated by expert pathologists according to eighth edition of the Union for International Cancer Control Tumor-Node-Metastasis (TNM) grading system. All patients underwent regional lymphadenectomy, and the existence of Tumor-Lymph Node-Metastasis (TNM) was pathologically examined. Total RNA was extracted from 4-µm-thick FFPE specimens by manual microdissection using an RNeasy FFPE Kit (Qiagen, Hilden, Germany). The complementary DNA (cDNA) synthesis was performed using PrimeScript RT Master Mix (RR036A) (Takara, Dalian, China). The quantitative reverse transcription–polymerase chain reaction (qRT-PCR) assays were performed with a ViiA 7 Dx RT-PCR System (Applied Biosystems, Foster City, USA) using PowerUp SYBR Green Master Mix (Applied Biosystems, Vilnius, Lithuania). The cycling conditions were as follows: 40 cycles of 95°C for 15 s and 60°C for 60 s. The relative expression of target genes was normalized against glyceraldehyde-3-phosphate dehydrogenase using the 2^−ΔCT method. Primer sequences are provided in Table S1.

2.5 Immunohistochemistry

LUAD tissues were fixed with 10% formalin and embedded in paraffin. Then, the tissues were cut into 5-µm-thick sections and incubated overnight with primary antibodies anti-CD3, anti-CD4, anti-CD8, anti-CD19, anti-CD20, anti-PD1 (Abcam, UK). The sections were subsequently incubated with a secondary antibody (Abcam, UK) at 37°C for 1.5 h and stained with a 3,3-diaminobenzidine solution.

2.6 Function enrichment and gene interaction analyses

Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed using “clusterProfiler” R package (Version 3.11) based on differentially expressed genes (absolute value of logFC > 1.5; P value < 0.01). GeneMANIA (https://genemania.org/) was used to find other genes related to
a set of input genes using a very large set of functional association data. Association data included protein and genetic interactions, pathways, co-expression, co-localization, and protein domain similarity.

2.7 Development and validation of the nomogram

Univariate and multivariate Cox analyses were performed to assess the independent prognostic ability of B-lineage-associated risk signature using “survival” R package (Version 3.5). Then, a concise nomogram of predicting the OS of LUAD was established using R package “rms” (Version 2.10), including four factors. In addition, the predictive accuracies of the nomogram and separate prognostic factors were compared using ROC analyses.

2.8 Statistical analysis

Statistical analyses were performed using R (Version 3.6.3) and GraphPad Prism 8. The Wilcoxon rank-sum test and Student t test were used to determine differences in comparison of two groups. All statistical tests were two-tailed with a statistical significance level set at 0.05 in this study.

3. Results

3.1 A landscape of immune infiltration of patients with LUAD

Immune cell infiltration and TME are vital in tumor immunity. In recent studies, MCP-counter was widely used to quantify the relative abundance of immune cell subpopulations through the expression of multiple immune-infiltrating cell markers, yielding robust results. A total of 400 patients from TCGA-LUAD were screened as TCGA cohort because of having relatively complete demographic information, clinical information, and survival information. MCP-counter was used to visualize the relative abundance of multiple immune-infiltrating cell subpopulations with Z score (Fig. 1A). The significant difference in the relative abundance of immune cell subpopulations between different samples was clearly observed. Among these immune cell subpopulations, patients were divided into low expression of B lineage (100 patients) and high expression of B lineage (300 patients). The relative abundance of B lineage significantly positively correlated with OS (Fig. 1B). However, MCP-counter was used to quantify the relative abundance of B lineage based on 400 samples in the TCGA cohort. It is difficult for individuals to quantify the abundance of B lineage. Therefore, a B-lineage-associated risk signature was constructed to assess the OS of patients with LUAD and guide individualized diagnosis and treatment strategies. The study design is shown in Fig. 1C.

3.2 Construction of a B-lineage-associated risk signature

RNA expression profiles of 400 samples in the TCGA cohort were used to construct a B-lineage-associated risk signature predicting the OS of patients with LUAD; the gene expression of total RNA is shown in Figure S1A. In the TCGA cohort, differently expressed genes were detected between low expression of B lineage (70 patients) and high expression of B lineage (330 patients), revealing that 1057
genes were statistically significantly differentially expressed, including 991 downregulated genes and 66 upregulated genes (Fig. S1B). Moreover, cluster analysis of these 1057 significantly differentially expressed genes in the TCGA cohort was performed (Table S1). A significant clustering was observed between the 2 groups of samples, confirming that these 1057 genes were statistically significantly differently expressed (Fig. S1C).

Furthermore, we filtered the differentially expressed genes with absolute value of logFC > 3 and P value < 0.01, including 95 downregulated genes and 1 upregulated genes, to identify genes with large differences between groups as B-lineage-associated risk signature candidate genes (Table S2). Further, 13 genes, including FDCSP, FCER2, CNR2, MS4A1, FCRL1, BLK, TNFRSF13B, CD19, FCRLA, CR2, GH1, KRT20, and ALB, with nonzero regression coefficients with 10-fold cross-validation were found to have maximum prognostic value according to LASSO Cox regression analysis (Fig. S1D and S1E). Finally, a 13-gene B-lineage-associated risk signature was constructed, and the risk score of this risk signature was calculated using the following formula:

\[
\text{B lineage-associated risk signature} = \sum \text{Coeff}_i \times (\text{Normalize Expression})_i
\]

The coefficient of each gene is shown in Table S4. Based on the B-lineage-associated risk signature, patients were divided into two subgroups. The optimal cutoff value was determined using the “surv_cutpoint” function of the “survminer” R package; the optimal cutoff value was −16.2 (Fig. S1F). The cutoff value in the TCGA cohort served as the cutoff value to assign patients into high-risk and low-risk groups across all patients with LUAD in the following analysis.

### 3.3 Evaluation and validation of the prognostic ability of B-lineage-associated risk signature

The prognostic capability of the B-lineage-associated risk signature in the TCGA cohort was evaluated. Due to the limited patient records available, the duration of treatment is unknown. However, the diversity of treatment methods in patient samples reflects the challenging variables that clinicians encounter when treating LUAD. The Kaplan–Meier analysis demonstrated that the patients in the high-risk group correlated with worse outcome (Fig. 2A). The risk signature distribution, OS, and 13-gene expression profile are shown in Fig. 2B. In addition, the time-dependent ROC curve analysis of the of B-lineage-associated risk signature in the TCGA cohort revealed a promising prognostic capability for OS (half-year AUC = 0.764, 1-year AUC = 0.646, 2-year AUC = 0.621, 5-year AUC = 0.635, and 7-year AUC = 0.622, Fig. 2C).

The risk signature was assessed in an independent validation cohort, meta-GEO cohort, including GSE29013, GSE30219, and GSE31908, to validate the robust ability of the B-lineage-associated risk signature to predict OS. The cohort contained 131 patients with LUAD having survival information and RNA expression profiles. The Kaplan–Meier analysis yielded consistent results that patients in the high-
risk group were positive related to worse clinical outcome (Fig. 2D). The risk signature distribution, OS, and 13-gene expression profile are shown in Fig. 2E. The time-dependent ROC curve analysis of the B-lineage-associated risk signature in the meta-GEO cohort validated the robustness of prognostic capability (half-year AUC = 0.75, 1-year AUC = 0.764, 2-year AUC = 0.665, 5-year AUC = 0.596, and 7-year AUC = 0.602, Fig. 2F). The aforementioned results indicated that the B-lineage-associated risk signature could predict OS.

### 3.4 Stratification analysis of the B-lineage-associated risk signature

Multiple clinical factors have a significant impact on the survival of patients with LUAD. The stratification analysis of the B-lineage-associated risk signature in several clinical subgroups was performed to verify that the B-lineage-associated risk signature was independently involved in predicting prognosis, without being manipulated by any clinical subgroup. The Kaplan–Meier survival analysis between high-risk and low-risk groups in these subgroups illustrated that risk signature was still a robust and independent marker for predicting OS in patients with different sexes (Fig. S2A and S2B), different ages (Fig. S2C and S2D), and different TNM stages (Fig. S2E and S2F).

### 3.5 Difference in immune status and immunotherapy benefits between high-risk and low-risk patients

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of differently expressed genes were performed to further explore the pathways of statistically differently expressed genes between patients with low expression of B lineage and patients with high expression of B lineage and also understand the potential biological processes affecting the prognosis of patients (absolute value of logFC > 1.5, \( P \) value < 0.01, 1057 genes, Fig. S3A and S3B). The GO analysis comprised enriched biological processes, cellular components, and molecular function. These genes were enriched in several immune-related biological processes, including B-cell activation, leukocyte migration, humoral immune response, and regulation of B-cell receptor signaling pathway. In molecular function, these genes were enriched in immunoglobulin binding. The KEGG analysis reflected that these genes were enriched in cytokine–cytokine receptor interaction. These results indicated that differently expressed genes between patients with low expression of B lineage and patients with high expression of B lineage were related to the tumor immune process, suggesting that tumors evade immune surveillance and cause different clinical outcomes due to differences in immune cell activation in the TME and differences in antigen presentation and signal transduction. Moreover, GeneMANIA online tool was used to observe the interaction of 13 risk signature–related genes (Fig. S3C). The result reflected that these genes were co-expressed and had close physical interactions. In addition, these genes had close relationship with several chemokine-related genes and B-cell surface marker–related genes. Moreover, we got consist result in the correlationship of 13 risk signature–related genes expression, which revealed a extensive co-regulation relationship (Fig. S3D). This finding suggested that these genes might have originated from
the same underlying structure and might affect the B-cell activation and antigen presentation process, thereby affecting the prognosis of patients with LUAD.

Recent studies have shown that the difference between the TME and immune cell infiltration can significantly change the recognition of tumor antigens, presentation of signals, and killing of tumor cells by the patient immune system. The expression of immune cell markers was detected to examine the relative abundance of tumor suppressor immune cell subpopulations in the TME between high-risk and low-risk groups. The tSNE plot revealed that two groups of patients in the TCGA cohort were divided into two different principal component clusters based on mRNA expression (Fig. 3A). The expression levels of MS4A1 (encoding CD20, marker of B cells, Fig. 3B), IGHG1 (marker of plasma cells, Fig. 3C), and CD19 (encoding CD19, marker of B cells, Fig. 3D) were significantly high in the low-risk groups, indicating higher abundance of the tumor suppressor B lineages. The expression levels of CD8A (encoding CD8, marker of CD8+ T cells, Fig. 3E), CD4 (encoding CD4, marker of CD4+ T cells, Fig. 3F), and CD3D (encoding CD3, marker of T cells, Fig. 3G) were also significantly high in the low-risk groups, indicating higher abundance of the tumor suppressor T-cell subpopulation.

Meanwhile, immune checkpoints inhibitors have been shown to exert antitumor effects by reversing tumor-immunosuppressive effects. The present study further investigated the relationship between the B-lineage-associated risk signature and the expression of immune checkpoints, including CTLA4, TIGIT, PDCD1, TIM3, and LAG3 (Fig. 3H–3L). These results showed that these immune checkpoints were highly expressed in low-risk patients. In addition, patients were divided into high-risk and low-risk groups by qRT-PCR in 16 patients with LUAD from Jiangsu Cancer Hospital (The primers shown in Table S4). Immunohistochemical analysis was performed on the surface proteins of the immune cells and important immune checkpoints on paraffin-embedded pathological sections of these patients, including CD20, CD19, CD8, CD4, CD3, and PD1 (Fig. 4A). Consistent results were obtained at the protein and RNA levels (Fig. 4B). Moreover, We continue to explore whether immunotherapy can benefit in the "immune activation" low-risk group. Unsurprisingly, B-lineage-associated risk signature and immunotherapy benefit showed a correlation trend (Fig. 4C) in GSE135222. These results indicated that high-risk and low-risk groups distinguished by the B-lineage-associated risk signature had different immune activation and efficiency of immune checkpoints axis, leading to different benefit from immunotherapy.

3.6 Construction and validation of a nomogram based on the B-lineage-associated risk signature

The predictive ability of the B-lineage-associated risk signature for prognosis was evaluated through univariate Cox regression analysis (P value < 0.05). Then, multivariate Cox regression was used to evaluate the B-lineage-associated risk signature score and several other clinical data, including TNM stage, lymph node invasion and age, as independent prognostic factors (P value < 0.05, Fig. 5A). A nomogram that integrated the B-lineage-associated risk signature and other independent clinical factors (lymphatic invasion, age, and TNM staging) was constructed to provide clinicians with a quantitative approach to predict the prognosis of patients with LUAD (Fig. 5B). Time-dependent ROC curve analysis
was used to compare the predictive accuracy between the nomogram, B-lineage-associated risk signature, age, and TNM stage in 1, 2, 5, and 7 years (Fig. 5C–5F). The nomogram model suggested higher prognostic accuracy for 1-, 2-, 5-, and 7-year OS with a larger AUC.

4. Discussion

LUAD is a malignant tumor with a high incidence worldwide. Early assessment of patient prognosis and effective immunotherapy biomarkers are very important. Traditional classification methods, including the TNM staging system, cannot cover the heterogeneity in molecular biology. Meanwhile, the research on the heterogeneity of the TME has become a hot issue in the field of tumor malignant progression, patient prognosis, and tumor immunotherapy(17–22). Evaluating the prognosis of patients with LUAD from the perspective of molecular biology and TME is very meaningful for individualized diagnosis and treatment.

In this study, a novel B-lineage-associated risk signature was constructed, which was significantly related to OS and tumor immune microenvironment. First, the MCP-counter algorithm was used to evaluate the immune cell infiltration of each sample in the TCGA-LUAD RNA-seq dataset. Recent studies have shown that B cells are related to the prognosis of patients in multiple cancer types and affect the immune response state of tumors(23, 24). At the same time, B-cell abundance significantly correlated with OS in patients with LUAD. A B-lineage-associated risk signature was constructed based on the TCGA cohort and validated in the meta-GEO cohort, which was significantly related to prognosis. The prognostic value of this signature was also independent of the known strong prognostic factors, such as sex, age, and tumor grade. Moreover, this signature affected tumor immune-related pathways and immune cell infiltration in tumor tissues. The molecular targets and several clinical factors were integrated into a new nomogram model with robust survival prediction, taking advantage of their complementary values.

A large number of clinical trials have shown that the combination of immune checkpoint inhibitors and chemotherapy can significantly improve the progression-free survival of patients with advanced NSCLC compared with conventional chemotherapy alone (25, 26). However, only part of patients can achieve a long-term, effective immune response from immunotherapy, and therefore a new immunotherapy strategy and research perspective is necessary(27). As an important component of tumor-infiltrating immune cells, B cells may become a breakthrough in regulating immune-related therapeutic targets.

B cells can regulate immune response function through a variety of signaling pathways. Tumor-infiltrating B cells have been reported to exist in a variety of solid tumors(28). B cells can inhibit the malignant progression of tumors by secreting immunoglobulins, promoting T-cell immune response, presenting tumor antigens, and directly killing tumor cells(29). B cells and their related pathways work together to promote the aggregation, maturation, and maintenance of tertiary lymphatic structures (TLS) (30). TLS is the lymphocyte aggregate formed in the chronic inflammatory response and similar in structure to the secondary lymphoid organs(31). TLS is defined as a CD20 + B-cell follicle surrounded by a CD3 + T-cell aggregate of DC-LAMP + mature dendritic cells(30, 32–34). In many solid tumors including...
NSCLC, TLS is associated with improved prognosis and immune response\(^{34, 35}\). A total of 13 B-cell-associated transcripts were screened using bioinformatics methods, revealing that they had a strong interaction and co-regulation relationship. Hence, it was possible that they were from the same structure in the sample.

In conclusion, the B-lineage-associated risk signature is a promising biomarker that divides patients into two subgroups with completely different clinical prognosis and immune status. It provides a view of the transcriptome level and TME to clarify the mechanism underlying different prognosis and efficacy of LUAD after immunotherapy.

**Declarations**

**Availability of data and material**

The data sets supporting the conclusion of this study are available from the “TCGAbiolinks” R package (Version 2.14.1; [https://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html](https://bioconductor.org/packages/release/bioc/html/TCGAbiolinks.html)) and GEO database ([https://www.ncbi.nlm.nih.gov/gds](https://www.ncbi.nlm.nih.gov/gds)).

**Ethics approval and consent to participate**

This study was approved by the Regional Ethics Committee at Nanjing Medical University. The experiments were undertaken with the understanding and written consent of each patient.

**Ethic approval and consent to participate**

The study was approved by the Regional Ethics Committee at Nanjing Medical University. The experiments were undertaken with the understanding and written consent of each patient. The study methodologies conformed to the standards set by the Declaration of Helsinki.

**Conflicts of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could role as a potential conflict of interest.

**Consent for publication**

Written informed consent for publication was obtained from all participants.

**Author contributions**

Zhang Yi, Yin Xuwen, and Wang Qi conceived and designed the study. Zhang Yi, Yin Xuwen, and Mao Qixing performed the analysis. Wang Qi, Liang Yingkuan, and Zhang Te wrote the manuscript. Song Xuming and Xia Wenjie helped with the statistical analysis. Zhang Yi and Chen Bing collected surgical
tissue samples and conducted pathological examinations. Jiang Feng, Xu Xinyu, Dong Gaochao and Xu Lin reviewed the draft. All authors read and approved the final manuscript.

Acknowledgments

None

Funding

This study was supported by the grants from the National Natural Science Foundation of China (Grant No. 82073211, 82002434, 82003106); The Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Innovation Team (CXTDA2017002); The Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent (JCRCA2016001); Young Talents Program of Jiangsu Cancer Hospital (23).

References

1. R. L. Siegel, K. D. Miller and A. Jemal: Cancer statistics, 2020. CA Cancer J Clin, 70(1), 7–30 (2020) doi:10.3322/caac.21590

2. V. Relli, M. Trerotola, E. Guerra and S. Alberti: Abandoning the Notion of Non-Small Cell Lung Cancer. Trends Mol Med, 25(7), 585–594 (2019) doi:10.1016/j.molmed.2019.04.012

3. A. Constantinidou, C. Aliferis and D. T. Trafalis: Targeting Programmed Cell Death – 1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacol Ther, 194, 84–106 (2019) doi:10.1016/j.pharmthera.2018.09.008

4. C. Manegold, A. C. Dingemans, J. E. Gray, K. Nakagawa, M. Nicolson, S. Peters, M. Reck, Y. L. Wu, O. T. Brustugun, L. Crino, E. Felip, D. Fennell, P. Garrido, R. M. Huber, A. Marabelle, M. Moniuszko, F. Mornex, S. Novello, M. Papotti, M. Perol, E. F. Smit, K. Syrigos, J. P. van Meerbeeck, N. van Zandwijk, J. C. Yang, C. Zhou and E. Vokes: The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol, 12(2), 194–207 (2017) doi:10.1016/j.jtho.2016.10.003

5. E. C. Ko, D. Raben and S. C. Formenti: The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res, 24(23), 5792–5806 (2018) doi:10.1158/1078-0432.CCR-17-3620

6. D. Uprety, S. J. Mandrekar, D. Wigle, A. C. Roden and A. A. Adjei: Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. J Thorac Oncol, 15(8), 1281–1297 (2020) doi:10.1016/j.jtho.2020.05.020

7. M. Ito, G. Ishii, K. Nagai, R. Maeda, Y. Nakano and A. Ochiai: Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest, 142(1), 151–158 (2012) doi:10.1378/chest.11-2458
8. R. Navab, D. Strumpf, B. Bandarchi, C. Q. Zhu, M. Pintilie, V. R. Rammarine, E. Ibrahimov, N. Radulovich, L. Leung, M. Barczyk, D. Panchal, C. To, J. J. Yun, S. Der, F. A. Shepherd, I. Jurisica and M. S. Tsao: Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. *Proc Natl Acad Sci U S A*, 108(17), 7160–5 (2011) doi:10.1073/pnas.1014506108

9. S. B. Lim, S. J. Tan, W. T. Lim and C. T. Lim: An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. *Nat Commun*, 8(1), 1734 (2017) doi:10.1038/s41467-017-01430-6

10. N. Dimitrova, V. Gocheva, A. Bhutkar, R. Resnick, R. M. Jong, K. M. Miller, J. Bendor and T. Jacks: Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. *Cancer Discov*, 6(2), 188–201 (2016) doi:10.1158/2159-8290.CD-15-0854

11. F. Veglia, M. Perego and D. Gabrilovich: Myeloid-derived suppressor cells coming of age. *Nat Immunol*, 19(2), 108–119 (2018) doi:10.1038/s41590-017-0022-x

12. R. M. Bremnes, L. T. Busund, T. L. Kilaer, S. Andersen, E. Richardsen, E. E. Paulsen, S. Hald, M. R. Khanehenkenari, W. A. Cooper, S. C. Kao and T. Donnem: The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. *J Thorac Oncol*, 11(6), 789–800 (2016) doi:10.1016/j.jtho.2016.01.015

13. J. Chen, Y. Tan, F. Sun, L. Hou, C. Zhang, T. Ge, H. Yu, C. Wu, Y. Zhu, L. Duan, L. Wu, N. Song, L. Zhang, W. Zhang, D. Wang, C. Chen, G. Jiang and P. Zhang: Single-cell transcriptome and antigen-immunoglobulin analysis reveals the diversity of B cells in non-small cell lung cancer. *Genome Biol*, 21(1), 152 (2020) doi:10.1186/s13059-020-02064-6

14. C. Wang, R. Yin, J. Dai, Y. Gu, S. Cui, H. Ma, Z. Zhang, J. Huang, N. Qin, T. Jiang, L. Geng, M. Zhu, Z. Pu, F. Du, Y. Wang, J. Yang, L. Chen, Q. Wang, Y. Jiang, L. Dong, Y. Yao, G. Jin, Z. Hu, L. Jiang, L. Xu and H. Shen: Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironmets in Chinese NSCLC patients. *Nat Commun*, 9(1), 2054 (2018) doi:10.1038/s41467-018-04492-2

15. T. C. Bruno, P. J. Ebner, B. L. Moore, O. G. Squalls, K. A. Waugh, E. B. Eruslanov, S. Singhal, J. D. Mitchell, W. A. Franklin, D. T. Merrick, M. D. McCarter, B. E. Palmer, J. A. Kern and J. E. Slansky: Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer Patients. *Cancer Immunol Res*, 5(10), 898–907 (2017) doi:10.1158/2326-6066.cir-17-0075

16. E. Becht, N. A. Giraldo, L. Lacroix, B. Buttard, N. Elarouci, F. Petitprez, J. Selves, P. Laurent-Puig, C. Sautes-Fridman, W. H. Fridman and A. de Reynies: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biol*, 17(1), 218 (2016) doi:10.1186/s13059-016-1070-5

17. M. Tahmasebi Birgani and V. Carloni: Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy. *Int J Mol Sci*, 18(2) (2017) doi:10.3390/ijms18020405

18. B. Ren, M. Cui, G. Yang, H. Wang, M. Feng, L. You and Y. Zhao: Tumor microenvironment participates in metastasis of pancreatic cancer. *Mol Cancer*, 17(1), 108 (2018) doi:10.1186/s12943-018-0858-1
19. M. R. Junttila and F. J. de Sauvage: Influence of tumour micro-environment heterogeneity on therapeutic response. *Nature*, 501(7467), 346–54 (2013) doi:10.1038/nature12626

20. Y. Komohara and M. Takeya: CAFs and TAMs: maestros of the tumour microenvironment. *J Pathol*, 241(3), 313–315 (2017) doi:10.1002/path.4824

21. A. Garcia-Gomez, J. Rodriguez-Ubrea and E. Ballestar: Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment. *Clin Immunol*, 196, 64–71 (2018) doi:10.1016/j.clim.2018.02.013

22. T. Frankel, M. P. Lanfranca and W. Zou: The Role of Tumor Microenvironment in Cancer Immunotherapy. *Adv Exp Med Biol*, 1036, 51–64 (2017) doi:10.1007/978-3-319-67577-0_4

23. F. Petitprez, A. de Reynies, E. Z. Keung, T. W. Chen, C. M. Sun, J. Calderaro, Y. M. Jeng, L. P. Hsiao, L. Lacroix, A. Bougouin, M. Moreira, G. Lacroix, I. Natario, J. Adam, C. Lucchesi, Y. H. Laizet, M. Toulmonde, M. A. Burgess, V. Bolejack, D. Reinke, K. M. Wani, W. L. Wang, A. J. Lazar, C. L. Roland, J. A. Wargo, A. Italiano, C. Sautes-Fridman, H. A. Tawbi and W. H. Fridman: B cells are associated with survival and immunotherapy response in sarcoma. *Nature*, 577(7791), 556–560 (2020) doi:10.1038/s41586-019-1906-8

24. B. A. Helmink, S. M. Reddy, J. Gao, S. Zhang, R. Basar, R. Thakur, K. Yizhak, M. Sade-Feldman, J. Blando, G. Han, V. Gopalakrishnan, Y. Xi, H. Zhao, R. N. Amaria, H. A. Tawbi, A. P. Cogdill, W. Liu, V. S. LeBleu, F. G. Kugersatzki, S. Patel, M. A. Davies, P. Hwu, J. E. Lee, J. E. Gershenwald, A. Lucci, R. Arora, S. Woodman, E. Z. Keung, P. O. Gaudreau, A. Reuben, C. N. Spencer, E. M. Burton, L. E. Haydu, A. J. Lazar, R. Zapassodi, C. W. Hudgens, D. A. Ledesma, S. Ong, M. Bailey, S. Warren, D. Rao, O. Krijgsman, E. A. Rozeman, D. Peeper, C. U. Blank, T. N. Schumacher, L. H. Butterfield, M. A. Zelazowska, K. M. McBride, R. Kalluri, J. Allison, F. Petitprez, W. H. Fridman, C. Sautes-Fridman, N. Hacohen, K. Rezvani, P. Sharma, M. T. Tetzlaff, L. Wang and J. A. Wargo: B cells and tertiary lymphoid structures promote immunotherapy response. *Nature*, 577(7791), 549–555 (2020) doi:10.1038/s41586-019-1922-8

25. M. D. Hellmann, L. Paz-Ares, R. Bernabe Caro, B. Zurawski, S. W. Kim, E. Carcereny Costa, K. Park, A. Alexandru, L. Lupinacci, E. de la Mora Jimenez, H. Sakai, I. Albert, A. Vergnenegre, S. Peters, K. Syrigos, F. Barlesi, M. Reck, H. Borghaei, J. R. Brahmer, K. J. O’Byrne, W. J. Geese, P. Bhagavatheeswaran, S. K. Rabindran, R. S. Kasinathan, F. E. Nathan and S. S. Ramalingam: Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *N Engl J Med*, 381(21), 2020–2031 (2019) doi:10.1056/NEJMoa1910231

26. J. Brahmer, K. L. Reckamp, P. Baas, L. Crino, W. E. Eberhardt, E. Poddubskaya, S. Antonia, A. Pluzanski, E. E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Aren Frontera, L. Havel, M. Steins, M. C. Garassino, J. G. Aerts, M. Domine, L. Paz-Ares, M. Reck, C. Baudelet, C. T. Harbison, B. Lestini and D. R. Spigel: Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*, 373(2), 123–35 (2015) doi:10.1056/NEJMo1504627

27. N. K. Altorki, G. J. Markowitz, D. Gao, J. L. Port, A. Saxena, B. Stiles, T. McGraw and V. Mittal: The lung microenvironment: an important regulator of tumour growth and metastasis. *Nat Rev Cancer*, 19(1), 9–31 (2019) doi:10.1038/s41568-018-0081-9
28. R. Tokunaga, M. Naseem, J. H. Lo, F. Battaglin, S. Soni, A. Puccini, M. D. Berger, W. Zhang, H. Baba and H. J. Lenz: B cell and B cell-related pathways for novel cancer treatments. *Cancer Treat Rev*, 73, 10–19 (2019) doi:10.1016/j.ctrv.2018.12.001

29. S. S. Wang, W. Liu, D. Ly, H. Xu, L. Qu and L. Zhang: Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. *Cell Mol Immunol*, 16(1), 6–18 (2019) doi:10.1038/s41423-018-0027-x

30. C. Sautes-Fridman, F. Petitprez, J. Calderaro and W. H. Fridman: Tertiary lymphoid structures in the era of cancer immunotherapy. *Nat Rev Cancer*, 19(6), 307–325 (2019) doi:10.1038/s41568-019-0144-6

31. C. Pitzalis, G. W. Jones, M. Bombardieri and S. A. Jones: Ectopic lymphoid-like structures in infection, cancer and autoimmunity. *Nat Rev Immunol*, 14(7), 447–62 (2014) doi:10.1038/nri3700

32. M. C. Dieu-Nosjean, J. Goc, N. A. Giraldo, C. Sautes-Fridman and W. H. Fridman: Tertiary lymphoid structures in cancer and beyond. *Trends Immunol*, 35(11), 571–80 (2014) doi:10.1016/j.it.2014.09.006

33. F. Posch, K. Silina, S. Leibl, A. Mundlein, H. Moch, A. Siebenhuner, P. Samaras, J. Riedl, M. Stotz, J. Szkandera, H. Stoger, M. Pichler, R. Stupp, M. van den Broek, P. Schraml, A. Gerger, U. Petrausch and T. Winder: Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. *Oncoimmunology*, 7(2), e1378844 (2018) doi:10.1080/2162402X.2017.1378844

34. K. Silina, A. Soltermann, F. M. Attar, R. Casanova, Z. M. Uckeley, H. Thut, M. Wandres, S. Isajevs, P. Cheng, A. Curioni-Fontecedro, P. Foukas, M. P. Levesque, H. Moch, A. Line and M. van den Broek: Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. *Cancer Res*, 78(5), 1308–1320 (2018) doi:10.1158/0008-5472.CAN-17-1987

35. J. Calderaro, F. Petitprez, E. Becht, A. Laurent, T. Z. Hirsch, B. Rousseau, A. Luciani, G. Amaddeo, J. Derman, C. Charpy, J. Zucman-Rossi, W. H. Fridman and C. Sautes-Fridman: Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. *J Hepatol*, 70(1), 58–65 (2019) doi:10.1016/j.jhep.2018.09.003

**Figures**
Figure 1

(A) A heatmap reflecting the relative abundance of immune microenvironment cell subpopulation in patients with lung adenocarcinoma in TCGA using MCP-counter R package. Expression profiles are normalized by z-score. (B) Kaplan-Meier survival curve analysis between high relative abundance of B lineage patients and low relative abundance B lineage patients. (C) The study design in this study.
Figure 2

(A) The Kaplan-Meier survival analysis in the TCGA cohort. (B) The risk signature (upper), the OS (middle) and the expression of 13 selected genes(bottom) in the TCGA cohort. (C) The time-dependent ROC curves of TCGA cohort. (D) The Kaplan-Meier survival analysis in the meta-GEO cohort. (E) The risk signature (upper), the OS (middle) and the expression of 13 selected genes(bottom) in the meta-GEO cohort. (F) The time-dependent ROC curves of the meta-GEO cohort.
Figure 3

The expression difference of several immune cells markers including (A) MS4A1 (encoding CD20, marker of B cells), (B) IGHG1 (marker of plasma cells), (C) CD19 (encoding CD19, marker of B cells), (D) CD8A (encoding CD8, marker of CD8+ T cells), (E) CD4 (encoding CD4, marker of CD4+ T cells), (F) CD3D (encoding CD3, marker of T cells) and (G-K) expression of several immune checkpoints.
Figure 4

Immunohistochemical analysis of patients in high-risk group and low-risk group. (A) H&E representative pictures and immunohistochemical representative pictures of anti-CD3, anti-CD4, anti-CD8, anti-CD19, anti-CD20, and anti-PD1 in high-risk LUAD patients. (B) The IHC-score of those above antigens in low-risk group and high-risk group. (C) B-lineage-associated risk signature and immunotherapy benefit distribution heatmap.
Figure 5

(A) Univariate cox regression analyses and multivariate cox regression analyses for lung adenocarcinoma patients in the TCGA cohort. Red indicates statistical significance (P-value < 0.05), and black indicates no statistical significance. (B) Nomogram for predicting the probability of 1-, 2-, 5- and 7-year OS for lung adenocarcinoma patients of TCGA cohort. Time-dependent ROC curve analyses of 4 factors, including age, TNM stage, the B lineage-associated risk signature and nomogram, 1-, 2-, 5- and 7-year in TCGA cohort.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Fig.S1.jpg
- FigS2.jpg
- Fig.S3.jpg
- tableS1primers.docx
- TableS2.xlsx
- TableS3.xlsx
- TableS4.docx